Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.

Plasma inflammation for predicting phenotypic conversion and clinical progression of autosomal dominant frontotemporal lobar degeneration

Open access

Abstract

Background: Measuring systemic inflammatory markers may improve clinical prognosis and help identify targetable pathways for treatment in patients with autosomal dominant forms of frontotemporal lobar degeneration (FTLD). Methods: We measured plasma concentrations of IL-6, TNFα and YKL-40 in pathogenic variant carriers ( MAPT, C9orf72, GRN ) and non-carrier family members enrolled in the ARTFL-LEFFTDS Longitudinal Frontotemporal Lobar Degeneration consortium. We evaluated associations between baseline plasma inflammation and rate of clinical and neuroimaging changes (linear mixed effects models with standardised (z) outcomes). We compared inflammation between asymptomatic carriers who remained clinically normal (‘asymptomatic non-converters’) and those who became symptomatic (‘asymptomatic converters’) using area under the curve analyses. Discrimination accuracy was compared with that of plasma neurofilament light chain (NfL). Results: We studied 394 participants (non-carriers=143, C9orf72 =117, GRN =62, MAPT =72). In MAPT , higher TNFα was associated with faster functional decline (B=0.12 (0.02, 0.22), p=0.02) and temporal lobe atrophy. In C9orf72, higher TNFα was associated with faster functional decline (B=0.09 (0.03, 0.16), p=0.006) and cognitive decline (B=−0.16 (−0.22, −0.10), p<0.001), while higher IL-6 was associated with faster functional decline (B=0.12 (0.03, 0.21), p=0.01). TNFα was higher in asymptomatic converters than non-converters (β=0.29 (0.09, 0.48), p=0.004) and improved discriminability compared with plasma NfL alone (ΔR 2 =0.16, p=0.007; NfL: OR=1.4 (1.03, 1.9), p=0.03; TNFα: OR=7.7 (1.7, 31.7), p=0.007). Conclusions: Systemic proinflammatory protein measurement, particularly TNFα, may improve clinical prognosis in autosomal dominant FTLD pathogenic variant carriers who are not yet exhibiting severe impairment. Integrating TNFα with markers of neuronal dysfunction like NfL could optimise detection of impending symptom conversion in asymptomatic pathogenic variant carriers and may help personalise therapeutic approaches.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/jnnp-2022-330866

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Association of baseline plasma TNFα with rate of change in disease severity among pathogenic MAPT variant carriers. (A) Participants with high baseline TNFα (>75th percentile, blue line) had a more rapid clinical disease progression (CDR+NACC FTLD sum of box score increase) over time than those with low baseline TNFα (<25th percentile, green line). (B) At baseline (cross-sectionally), voxel-based morphometry analysis revealed higher plasma TNFα was associated with lower brain volume in the left anterior temporal lobe (blue=p<0.05 after familywise error correction using 5000 permutations with threshold-free cluster enhancement. Longitudinally, Bayesian linear mixed-effects analyses revealed widespread regions where higher baseline plasma TNFα was associated with significantly faster atrophy rates, with the most rapid atrophy (red areas) occurring in medial temporal structures (threshold using posterior probability maps and p<0.05 alpha). CDR, Clinical Dementia Rating; FTLD, frontotemporal lobar degeneration; NACC, National Alzheimer’s Coordinating Center; SB, Sum of Boxes.
Figure 1 Association of baseline plasma TNFα with rate of change in disease severity among pathogenic MAPT variant carriers. (A) Participants with high baseline TNFα (>75th percentile, blue line) had a more rapid clinical disease progression (CDR+NACC FTLD sum of box score increase) over time than those with low baseline TNFα (<25th percentile, green line). (B) At baseline (cross-sectionally), voxel-based morphometry analysis revealed higher plasma TNFα was associated with lower brain volume in the left anterior temporal lobe (blue=p<0.05 after familywise error correction using 5000 permutations with threshold-free cluster enhancement. Longitudinally, Bayesian linear mixed-effects analyses revealed widespread regions where higher baseline plasma TNFα was associated with significantly faster atrophy rates, with the most rapid atrophy (red areas) occurring in medial temporal structures (threshold using posterior probability maps and p<0.05 alpha). CDR, Clinical Dementia Rating; FTLD, frontotemporal lobar degeneration; NACC, National Alzheimer’s Coordinating Center; SB, Sum of Boxes.CC BY-NC · PubMed Central
Figure 2 Association baseline plasma IL-6 with rate of change in disease severity among pathogenic C9orf72 variant carriers. (A) Participants with high baseline IL-6 (>75th percentile, blue line) had a more rapid clinical disease progression (CDR+NACC FTLD sum of box score increase) over time than those with low baseline IL-6 (<25th percentile, green line). (B) At baseline (cross-sectionally), voxel-based morphometry analyses revealed regions with a trend towards an association of higher IL-6 with lower brain volume predominantly in lateral parietal and medial parietal/precuneus regions (blue=p<0.10 after familywise error correction using 5000 permutations with threshold-free cluster enhancement). Bayesian linear mixed-effects analyses did not support a significant association of baseline plasma IL-6 concentrations with the rates of brain atrophy longitudinally. CDR, Clinical Dementia Rating; FTLD, frontotemporal lobar degeneration; NACC, National Alzheimer’s Coordinating Center; SB, Sum of Boxes.
Figure 2 Association baseline plasma IL-6 with rate of change in disease severity among pathogenic C9orf72 variant carriers. (A) Participants with high baseline IL-6 (>75th percentile, blue line) had a more rapid clinical disease progression (CDR+NACC FTLD sum of box score increase) over time than those with low baseline IL-6 (<25th percentile, green line). (B) At baseline (cross-sectionally), voxel-based morphometry analyses revealed regions with a trend towards an association of higher IL-6 with lower brain volume predominantly in lateral parietal and medial parietal/precuneus regions (blue=p<0.10 after familywise error correction using 5000 permutations with threshold-free cluster enhancement). Bayesian linear mixed-effects analyses did not support a significant association of baseline plasma IL-6 concentrations with the rates of brain atrophy longitudinally. CDR, Clinical Dementia Rating; FTLD, frontotemporal lobar degeneration; NACC, National Alzheimer’s Coordinating Center; SB, Sum of Boxes.CC BY-NC · PubMed Central
Figure 3 Baseline plasma inflammatory marker concentration differences between asymptomatic non-converter participants (CDR+NACC FTLD Global=0 at all visits) and asymptomatic converter participants (CDR+NACC FTLD Global=0 at baseline and >0.5 at a future visit). (A, B) Baseline plasma TNFα was statistically significantly higher in asymptomatic converters than asymptomatic non-converters (β=0.29 (0.09, 0.48), p=0.004) and showed fair discrimination accuracy between groups (AUC=0.72). There were no statistically significant differences in plasma IL-6 (C, D) nor YKL-40 (E, F) between asymptomatic converters and asymptomatic non-converters, and discrimination accuracy was insufficient (AUC <0.70) for both. Separate box-and-whisker plots are shown for each gene group for visualisation only (figure 4A,C,E). Gene groups were combined for all analyses. AUC, area under the curve; CDR, Clinical Dementia Rating; FTLD, frontotemporal lobar degeneration; NACC, National Alzheimer’s Coordinating Centre; SB, Sum of Boxes.
Figure 3 Baseline plasma inflammatory marker concentration differences between asymptomatic non-converter participants (CDR+NACC FTLD Global=0 at all visits) and asymptomatic converter participants (CDR+NACC FTLD Global=0 at baseline and >0.5 at a future visit). (A, B) Baseline plasma TNFα was statistically significantly higher in asymptomatic converters than asymptomatic non-converters (β=0.29 (0.09, 0.48), p=0.004) and showed fair discrimination accuracy between groups (AUC=0.72). There were no statistically significant differences in plasma IL-6 (C, D) nor YKL-40 (E, F) between asymptomatic converters and asymptomatic non-converters, and discrimination accuracy was insufficient (AUC <0.70) for both. Separate box-and-whisker plots are shown for each gene group for visualisation only (figure 4A,C,E). Gene groups were combined for all analyses. AUC, area under the curve; CDR, Clinical Dementia Rating; FTLD, frontotemporal lobar degeneration; NACC, National Alzheimer’s Coordinating Centre; SB, Sum of Boxes.CC BY-NC · PubMed Central
Figure 4 Added value of plasma TNFα to plasma NfL for discriminating asymptomatic converters from asymptomatic non-converters (all three gene groups combined). In a subset of participants with both markers (N=13 converters, N=55 non-converters), both plasma NfL (AUC=0.80) and plasma TNFα (AUC=0.75) independently discriminated asymptomatic converters from non-converters. The AUC for NfL and TNFα combined increased to 0.88. There was a statistically significant increase in classification accuracy after adding plasma TNFα to the model with plasma NfL only (ΔR2=0.16; NfL: OR=1.4 (1.03, 1.9), p=0.03; TNFα: OR=7.7 (1.7, 31.7), p=0.007). AUC, area under the curve; NfL, neurofilament light.
Figure 4 Added value of plasma TNFα to plasma NfL for discriminating asymptomatic converters from asymptomatic non-converters (all three gene groups combined). In a subset of participants with both markers (N=13 converters, N=55 non-converters), both plasma NfL (AUC=0.80) and plasma TNFα (AUC=0.75) independently discriminated asymptomatic converters from non-converters. The AUC for NfL and TNFα combined increased to 0.88. There was a statistically significant increase in classification accuracy after adding plasma TNFα to the model with plasma NfL only (ΔR2=0.16; NfL: OR=1.4 (1.03, 1.9), p=0.03; TNFα: OR=7.7 (1.7, 31.7), p=0.007). AUC, area under the curve; NfL, neurofilament light.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 41 references

Research works printed but not linked: 1

  1. 10.1037/0022-3514.46.6.1349 · DOI · Paper page

Cited by

See all 16

Metadata

Authors
Asken, B. M., Ljubenkov, P. A., Staffaroni, A. M., Casaletto, K. B., Vandevrede, L., Cobigo, Y., Rojas-Rodriguez, J. C., Rankin, K. P., Kornak, J., Heuer, H., Shigenaga, J., Appleby, B. S., Bozoki, A. C., Domoto-Reilly, K., Ghoshal, N., Huey, E., Litvan, I., Masdeu, J. C., Mendez, M. F., Pascual, B., Pressman, P., Tartaglia, M. C., Kremers, W., Forsberg, L. K., Boeve, B. F., Boxer, A. L., Rosen, H. J., & Kramer, J. H.
Affiliations
  • University of California, San Francisco (US)
  • San Francisco VA Medical Center (US)
  • Case Western Reserve University (US)
  • University of North Carolina at Chapel Hill (US)
  • Washington University in St. Louis (US)
  • Columbia University (US)
  • University of California San Diego (US)
  • Houston Methodist (US)
  • University of California, Los Angeles (US)
  • University of Colorado Anschutz (US)
  • University of Toronto (CA)
  • Mayo Clinic (US)
Corresponding author
Asken, Breton M
Venue
Journal of Neurology, Neurosurgery & Psychiatry
Publisher
BMJ
Published
2023-03-28
Volume
94
Issue
7
Pages
541-549
ISSN
  • 0022-3050 (ISSN-L)
  • 1468-330X
OpenAlex
W4361020091
Cited by
16
References
41
Citations by year
2026: 3 · 2025: 6 · 2024: 7
FWCI
2.72
Type
journal article
Language
en
Open access
Locations
  • Journal of Neurology Neurosurgery & Psychiatry (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • eScholarship (California Digital Library) (submittedVersion, cc-by-nc)
  • HighWire Press Open Archive (submittedVersion)
Funders
  • National Institute on Aging and the National Institute of Neurological Diseases and Stroke (U01 AG045390, U19 AG063911)
  • National Institute of Neurological Diseases and Stroke and National Center for Advancing Translational Sciences (U54 NS092089)
Topics
  • Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Keywords
systemic inflammation, TNF-α, interleukin-6, YKL-40, plasma neurofilament light chain, C9orf72, gene regulatory networks, MAPT, asymptomatic carriers, phenotypic conversion, clinical progression, functional decline, cognitive decline, temporal lobe atrophy, biomarkers, disease prediction, neuroinflammation
MeSH terms
C9orf72 Protein, Humans, Inflammation, Mutation, Tumor Necrosis Factor-alpha, Interleukin-6, tau Proteins, Disease Progression, Frontotemporal Lobar Degeneration, Frontotemporal Dementia

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Plasma inflammation for predicting phenotypic conversion and clinical progression of autosomal dominant frontotemporal lobar degeneration. https://app.cochat.ai/papers/10.1136/jnnp-2022-330866
The paper
Asken, B. M., Ljubenkov, P. A., Staffaroni, A. M., Casaletto, K. B., Vandevrede, L., Cobigo, Y., Rojas-Rodriguez, J. C., Rankin, K. P., Kornak, J., Heuer, H., Shigenaga, J., Appleby, B. S., Bozoki, A. C., Domoto-Reilly, K., Ghoshal, N., Huey, E., Litvan, I., Masdeu, J. C., Mendez, M. F., . . . Kramer, J. H. (2023). Plasma inflammation for predicting phenotypic conversion and clinical progression of autosomal dominant frontotemporal lobar degeneration. Journal of Neurology, Neurosurgery & Psychiatry. https://doi.org/10.1136/jnnp-2022-330866

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.